Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
Digirad delivers convenient, effective, and efficient healthcare solutions on an a...
Digirad delivers convenient, effective, and eff...
ContraFect is a clinical-stage biotechnology company focused on discovering and de...
ContraFect is a clinical-stage biotechnology co...
Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a ...
Fluidigm (NASDAQ:FLDM) is an industry-leading b...
Advaxis was founded on the vision that no one should suffer from the burdens of ca...
Advaxis was founded on the vision that no one s...
Osmotica Pharmaceuticals plc is a fully-integrated biopharmaceutical company focus...
Osmotica Pharmaceuticals plc is a fully-integra...
Sanofi is dedicated to supporting people through their health challenges. We are a...
Sanofi is dedicated to supporting people throug...
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology compa...
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a...
Join the National Investor Network and get the latest information with your interests in mind.